{"id":66588,"date":"2026-05-28T21:14:32","date_gmt":"2026-05-28T13:14:32","guid":{"rendered":"https:\/\/flcube.com\/?p=66588"},"modified":"2026-05-28T21:14:33","modified_gmt":"2026-05-28T13:14:33","slug":"viridian-therapeutics-secures-commercial-manufacturing-agreement-with-wuxi-biologics-for-veligrotug-anti-igf-1r-antibody-advances-toward-thyroid-eye-disease-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66588","title":{"rendered":"Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug \u2013 Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Viridian Therapeutics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/VRDN:NASDAQ\">NASDAQ: VRDN<\/a>), a U.S.-based developer of antibodies for rare autoimmune conditions, has entered into a commercial manufacturing services agreement with <strong>WuXi Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2269:HKG\">HKG: 2269<\/a>) earlier this week. Under the terms, WuXi Biologics will manufacture and supply long-term commercial quantities of <strong>veligrotug (VRDN-001)<\/strong> drug substance and drug product for commercial use in treating thyroid eye disease.<\/p>\n\n\n\n<h2 id=\"h-manufacturing-partnership-framework\" class=\"wp-block-heading\">Manufacturing Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Viridian Therapeutics, Inc. &amp; WuXi Biologics (Cayman) Inc.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Veligrotug (VRDN-001) \u2013 anti-insulin-like growth factor-1 receptor (IGF-1R) antibody<\/td><\/tr><tr><td><strong>Supply Arrangement<\/strong><\/td><td>Non-exclusive commercial manufacturing agreement<\/td><\/tr><tr><td><strong>Pricing Model<\/strong><\/td><td>Volume-based structure with fixed pricing until December 31, 2026<\/td><\/tr><tr><td><strong>Post-2026 Terms<\/strong><\/td><td>Annual price adjustments based on volume commitments<\/td><\/tr><tr><td><strong>Flexibility<\/strong><\/td><td>Viridian retains option to source from alternative manufacturers<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-therapeutic-application\" class=\"wp-block-heading\">Product Profile &amp; Therapeutic Application<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Veligrotug (VRDN-001) \u2013 monoclonal antibody targeting IGF-1R<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Intravenous infusion formulation<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Active and chronic thyroid eye disease (TED)<\/li>\n\n\n\n<li><strong>Therapeutic Positioning:<\/strong> Expected to become treatment of choice for TED patients<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks IGF-1R signaling pathway implicated in TED pathogenesis<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Advanced toward commercial launch<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-greater-china-licensing-structure\" class=\"wp-block-heading\">Greater China Licensing Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Timeline<\/th><th>Transaction<\/th><th>Parties Involved<\/th><th>Rights Granted<\/th><\/tr><\/thead><tbody><tr><td><strong>October 2020<\/strong><\/td><td>Initial License<\/td><td>Viridian \u2192 Zenas BioPharma<\/td><td>Exclusive rights to develop, manufacture, and commercialize veligrotug and other IGF-1R drugs in Greater China<\/td><\/tr><tr><td><strong>2024<\/strong><\/td><td>Sub-license<\/td><td>Zenas BioPharma \u2192 Zai Lab Limited<\/td><td>Greater China rights for veligrotug specifically<\/td><\/tr><tr><td><strong>Current<\/strong><\/td><td>Global Manufacturing<\/td><td>Viridian \u2192 WuXi Biologics<\/td><td>Worldwide commercial supply (excluding Greater China territory held by Zai Lab)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This multi-tiered licensing structure demonstrates the complex international commercialization strategy for veligrotug, with separate arrangements covering different geographic territories and development phases.<\/p>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-impact\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing Security:<\/strong> WuXi Biologics provides reliable, high-quality commercial-scale production capacity<\/li>\n\n\n\n<li><strong>Cost Certainty:<\/strong> Fixed pricing through end of 2026 protects Viridian from near-term cost volatility<\/li>\n\n\n\n<li><strong>Supply Chain Diversification:<\/strong> Non-exclusive arrangement maintains flexibility and competitive pricing leverage<\/li>\n\n\n\n<li><strong>Global Commercial Readiness:<\/strong> Agreement supports anticipated commercial launch in key markets outside Greater China<\/li>\n\n\n\n<li><strong>Thyroid Eye Disease Market:<\/strong> Addresses significant unmet need in rare autoimmune condition affecting quality of life<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-outlook\" class=\"wp-block-heading\">Competitive Landscape &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TED Treatment Gap:<\/strong> Limited therapeutic options currently available for chronic thyroid eye disease<\/li>\n\n\n\n<li><strong>Veligrotug Differentiation:<\/strong> Targeted IGF-1R inhibition offers potential advantages over existing approaches<\/li>\n\n\n\n<li><strong>Commercial Timeline:<\/strong> Manufacturing agreement positions Viridian for rapid market entry upon regulatory approvals<\/li>\n\n\n\n<li><strong>Greater China Parallel Path:<\/strong> Separate commercialization track through Zai Lab ensures comprehensive global coverage<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Orphan drug designation and premium pricing potential in rare disease indication<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Viridian Therapeutics&#8217; manufacturing agreement with WuXi Biologics, including commercial expectations for veligrotug and regulatory timelines. Actual results may differ due to risks including regulatory approvals, manufacturing scale-up challenges, market adoption, and competitive dynamics in the thyroid eye disease therapeutic area.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/3a421a23-d2c8-4a15-a4db-4dcba0f52c4b.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 3a421a23-d2c8-4a15-a4db-4dcba0f52c4b.\"><\/object><a id=\"wp-block-file--media-d521fffe-c4cf-44da-b235-91c15c796207\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/3a421a23-d2c8-4a15-a4db-4dcba0f52c4b.pdf\">3a421a23-d2c8-4a15-a4db-4dcba0f52c4b<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/3a421a23-d2c8-4a15-a4db-4dcba0f52c4b.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d521fffe-c4cf-44da-b235-91c15c796207\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Viridian Therapeutics, Inc. (NASDAQ: VRDN), a U.S.-based developer of antibodies for rare autoimmune conditions, has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[19,952,4760,4759,292],"class_list":["post-66588","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cro-cmo-cdmo","tag-hkg-2269","tag-nasdaq-vrdn","tag-viridian-therapeutics","tag-wuxi-biologics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug \u2013 Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Viridian Therapeutics, Inc. (NASDAQ: VRDN), a U.S.-based developer of antibodies for rare autoimmune conditions, has entered into a commercial manufacturing services agreement with WuXi Biologics (HKG: 2269) earlier this week. Under the terms, WuXi Biologics will manufacture and supply long-term commercial quantities of veligrotug (VRDN-001) drug substance and drug product for commercial use in treating thyroid eye disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66588\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug \u2013 Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment\" \/>\n<meta property=\"og:description\" content=\"Viridian Therapeutics, Inc. (NASDAQ: VRDN), a U.S.-based developer of antibodies for rare autoimmune conditions, has entered into a commercial manufacturing services agreement with WuXi Biologics (HKG: 2269) earlier this week. Under the terms, WuXi Biologics will manufacture and supply long-term commercial quantities of veligrotug (VRDN-001) drug substance and drug product for commercial use in treating thyroid eye disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66588\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T13:14:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-28T13:14:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66588#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66588\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug \u2013 Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment\",\"datePublished\":\"2026-05-28T13:14:32+00:00\",\"dateModified\":\"2026-05-28T13:14:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66588\"},\"wordCount\":474,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"HKG: 2269\",\"NASDAQ: VRDN\",\"Viridian Therapeutics\",\"WuXi Biologics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66588#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66588\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66588\",\"name\":\"Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug \u2013 Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-28T13:14:32+00:00\",\"dateModified\":\"2026-05-28T13:14:33+00:00\",\"description\":\"Viridian Therapeutics, Inc. (NASDAQ: VRDN), a U.S.-based developer of antibodies for rare autoimmune conditions, has entered into a commercial manufacturing services agreement with WuXi Biologics (HKG: 2269) earlier this week. Under the terms, WuXi Biologics will manufacture and supply long-term commercial quantities of veligrotug (VRDN-001) drug substance and drug product for commercial use in treating thyroid eye disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66588#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66588\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66588#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug \u2013 Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug \u2013 Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Viridian Therapeutics, Inc. (NASDAQ: VRDN), a U.S.-based developer of antibodies for rare autoimmune conditions, has entered into a commercial manufacturing services agreement with WuXi Biologics (HKG: 2269) earlier this week. Under the terms, WuXi Biologics will manufacture and supply long-term commercial quantities of veligrotug (VRDN-001) drug substance and drug product for commercial use in treating thyroid eye disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66588","og_locale":"en_US","og_type":"article","og_title":"Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug \u2013 Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment","og_description":"Viridian Therapeutics, Inc. (NASDAQ: VRDN), a U.S.-based developer of antibodies for rare autoimmune conditions, has entered into a commercial manufacturing services agreement with WuXi Biologics (HKG: 2269) earlier this week. Under the terms, WuXi Biologics will manufacture and supply long-term commercial quantities of veligrotug (VRDN-001) drug substance and drug product for commercial use in treating thyroid eye disease.","og_url":"https:\/\/flcube.com\/?p=66588","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-28T13:14:32+00:00","article_modified_time":"2026-05-28T13:14:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66588#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66588"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug \u2013 Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment","datePublished":"2026-05-28T13:14:32+00:00","dateModified":"2026-05-28T13:14:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66588"},"wordCount":474,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CRO \/ CMO \/ CDMO","HKG: 2269","NASDAQ: VRDN","Viridian Therapeutics","WuXi Biologics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66588#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66588","url":"https:\/\/flcube.com\/?p=66588","name":"Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug \u2013 Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-28T13:14:32+00:00","dateModified":"2026-05-28T13:14:33+00:00","description":"Viridian Therapeutics, Inc. (NASDAQ: VRDN), a U.S.-based developer of antibodies for rare autoimmune conditions, has entered into a commercial manufacturing services agreement with WuXi Biologics (HKG: 2269) earlier this week. Under the terms, WuXi Biologics will manufacture and supply long-term commercial quantities of veligrotug (VRDN-001) drug substance and drug product for commercial use in treating thyroid eye disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66588#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66588"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66588#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug \u2013 Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66588"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66588\/revisions"}],"predecessor-version":[{"id":66590,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66588\/revisions\/66590"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}